raloxifene hydrochloride has been researched along with Fractures, Bone in 141 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (6.38) | 18.2507 |
| 2000's | 103 (73.05) | 29.6817 |
| 2010's | 27 (19.15) | 24.3611 |
| 2020's | 2 (1.42) | 2.80 |
| Authors | Studies |
|---|---|
| Fukunaga, M; Hagino, H; Mori, S; Nakamura, T; Ohta, H; Orimo, H; Shiraki, M; Soen, S; Sone, T; Tanaka, S; Uemura, Y | 1 |
| Allen, MR; Jacobson, AM; Metzger, CE; Rai, RK; Saldivar, R; Surowiec, RK; Wallace, JM | 1 |
| Barry, MJ; Cooke, M; Denberg, TD; Fitterman, N; Forciea, MA; Harris, RP; Humphrey, LL; Kansagara, D; McLean, RM; Mir, TP; Qaseem, A; Schünemann, HJ | 1 |
| Collister, D; Connelly, K; Tangri, N | 1 |
| Adamkovicova, M; Babosova, R; Galbavy, D; Grosskopf, B; Lukacova, M; Martiniakova, M; Mondockova, V; Omelka, R | 1 |
| Allen, MR; Berman, A; Powell, KM; Pulliam, A; Skaggs, C; Wallace, JM | 1 |
| Amling, M; Beil, FT; Ignatius, A; Jeschke, A; Khadem, S; Marshall, RP; Pogoda, P; Spiro, AS | 1 |
| Fu, R; Griffin, JC; Nelson, HD; Smith, ME | 1 |
| Kulkarni, PM; Li, W; Qu, Y | 1 |
| Cai, Z; Tsujimoto, M; Uesaka, H | 1 |
| Diab, DL; Watts, NB | 1 |
| Alam, J; Burge, R; Gold, DT; Naegeli, AN; Shen, W; Shih, T; Silverman, S | 1 |
| Bouvet, A; Caruba, T; Pouchot, J; Sabatier, B; Savoldelli, V | 1 |
| Burge, R; Flynn, JA; Fujiwara, S; Graham-Clarke, P; Hamaya, E; Sato, M | 1 |
| Abrahamsen, B; Hoff, M; Langhammer, A; Meyer, HE; Schei, B; Skurtveit, S; Syversen, U; Søgaard, AJ | 1 |
| Compston, J | 2 |
| Fan, CP; Li, Z; Mellström, D; Modi, A; Sajjan, S; Salomonsson, S; Waern, E; Yang, X | 1 |
| Mershon, JL; Schoenfeld, MJ; Stock, JL | 1 |
| Chao, HT; Cheng, MH; Lee, WL; Wang, PH | 1 |
| Barrett-Connor, E; Cauley, JA; Collins, P; Geiger, MJ; Grady, D; Kornitzer, M; Mershon, J; Mosca, L; Song, J; Wenger, NK | 1 |
| Abrahamsen, B; Eiken, P; Roerholt, C | 1 |
| Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L | 1 |
| Ohta, H | 4 |
| Laroche, M | 1 |
| Pepersack, T | 1 |
| Verhaar, HJ | 1 |
| Inaba, M; Shidara, K | 1 |
| Alexander, IM | 1 |
| Blond, B | 1 |
| Azuma, K | 1 |
| Rawlins, S | 1 |
| Altunay, H; Bilgili, H; Gecit, MR; Keskin, D; Tasci, A | 1 |
| Fu, R; Griffin, JC; Humphrey, L; Nelson, HD; Nygren, P; Smith, ME | 1 |
| Becker, C | 1 |
| Li, W; Qu, Y | 1 |
| Cochet, T; Cohade, C; Pouillès, JM; Ribot, C; Trémollieres, F | 1 |
| Borgström, F; Burge, RT; Ivergård, M; Kanis, J; Ström, O; Tosteson, AN | 1 |
| Brandi, ML | 1 |
| Arnsten, JH; Blackwell, T; Cummings, SR; Ensrud, KE; Ishani, A; Melamed, ML; Neugarten, J; Silbiger, SR | 1 |
| Vogel, VG | 1 |
| Schmidt, C | 1 |
| Mori, S | 1 |
| Langdahl, B; Mosekilde, L; Vestergaard, P | 1 |
| Hadji, P | 1 |
| Pouillès, JM; Ribot, C; Trémollières, F | 1 |
| Pols, HA; Wittenberg, J | 1 |
| Välimäki, MJ | 1 |
| Akiyama, T; Cao, Y; Komatsubara, S; Ma, L; Mashiba, T; Miyamoto, K; Mori, S; Norimatsu, H; Sato, M; Shi, L; Westmore, MS | 1 |
| Baranauskaite, A; Savickiene, A | 1 |
| Begerow, B; Minne, HW; Pfeifer, M; Pollähne, W | 1 |
| Delmas, PD; Fontana, A | 1 |
| Begerow, B; Minne, HW; Pfeifer, M | 1 |
| Reincke, M | 1 |
| Felsenberg, D; Glüer, CC; Mühlenbacher, D; Nickelsen, T; Pavo, I; Payer, J; Quail, D; Reginster, JY; Resch, H; Schmitt, H; Stepan, J | 1 |
| Martens, MG | 1 |
| Adachi, JD; Crans, GG; Delmas, PD; Genant, HK; Siris, E; Stock, JL; Wong, M | 1 |
| Yoh, K | 1 |
| Franzson, L; Hansdóttir, H; Prestwood, K; Sigurdsson, G | 1 |
| Cheung, AM; Diaz-Granados, N; Dodin, S; Feig, DS; Kapral, M | 1 |
| McCombs, JS; McLaughlin-Miley, C; Shi, J; Thiebaud, P | 1 |
| László, A | 1 |
| Del Puente, A; Esposito, A; Lello, S; Migliaccio, S; Ott, SM | 1 |
| Zizic, TM | 1 |
| Nakamura, T | 1 |
| Hagino, H | 1 |
| Miki, T; Tomiyoshi, Y | 1 |
| Hamaya, E; Kobayashi, H | 1 |
| Hosking, DJ; Pande, I | 1 |
| Brewer, N; Davis, S; De Nigris, E; Jones, ML; Oakley, J; Stevenson, M | 1 |
| Diehr, S; Mijal, S; Nashelsky, J | 1 |
| Adachi, JD; Cranney, A | 1 |
| Cummings, SR; Diez-Perez, A; Eastell, R; Goemaere, S; Harris, ST; Kulkarni, PM; Qu, Y; Siddhanti, SR; Siris, ES; Song, J; Stock, JL; Wong, M; Zanchetta, JR | 1 |
| Case, M; Qu, Y | 1 |
| Sambrook, P | 1 |
| Takada, J | 1 |
| Devogelaer, JP; Reginster, JY | 1 |
| Duerring, SA; Emmett, MK; Lester, MD; Pfister, AK; Saville, PD; Welch, CA | 1 |
| de Vernejoul, MC | 1 |
| Audran, M; Chappard, D; Hoppé, E; Legrand, E | 1 |
| Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Lippman, SM; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N | 1 |
| Miki, T; Tamura, A | 1 |
| Hamaya, E; Huang, QR; Liu, JL; Morii, H; Nakamura, T; Qu, Y; Thiebaud, D; Zhu, HM | 1 |
| Kaji, H; Sugimoto, T | 1 |
| Kim, SH; Oh, JM; Shin, HT; Shin, WG; Song, EK; Yeom, JH | 1 |
| Qu, Y; Sarkar, S | 1 |
| Adami, S; Agnusdei, D; Gentilella, R; Iori, N; Isaia, G; Luisetto, G; Minisola, S; Nuti, R; Sinigaglia, L | 1 |
| Roux, C | 1 |
| Barna, A; Bourgoin, M; Briot, K; Chapurlat, R; Christin-Maitre, S; Cortet, B; Costagliola, D; Diebolt, V; Dumarcet, N; Lacoin, F; Letombe, B; Nouyrigat, E; Oberlin, F; Orcel, P; Ravaud, P; Roux, C; Seret, P; Thomas, T; Veyries, ML; Vogel, JY; Yoldjian, I | 1 |
| Cauley, JA; Gaich, CL; Kendler, D; Kulkarni, PM; Lewiecki, EM; Lorraine, J; Plouffe, L; Qu, Y; Recker, RR; Recknor, CP; Rooney, TW; Stock, JL; Utian, WH; Wong, M | 1 |
| Minshall, ME; Moses, KH; Shen, W; Silverman, SL; Xie, S | 1 |
| Järvinen, TL; Kannus, P; Sievänen, H | 1 |
| Johnston, JA; Klein, R; Meadows, ES; Ohsfeldt, RL; Rousculp, MD; Smolen, L | 1 |
| Allen, MR; Burr, DB; Hobbs, WA; Hogan, HA; Koivuniemi, AS; Koivuniemi, MC | 1 |
| Rizzoli, R | 1 |
| Agnusdei, D; Barrett-Connor, E; Cauley, JA; Ensrud, KE; Grady, D; Khaw, KT; Mosca, L; Stock, JL; Zhao, Q | 1 |
| González Macías, J; Olmos Martínez, JM | 1 |
| Adami, S; Agnusdei, D; Gentilella, R; Isaia, G; Luisetto, G; Minisola, S; Nuti, R; Silvestri, S; Sinigaglia, L | 1 |
| Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M | 1 |
| Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T | 1 |
| Bush, TL; Cole, RC; Flaws, JA | 1 |
| Broy, S; Civitelli, R; Fleischmann, R; Gagel, R; Khosla, S; Lucas, M; Lukert, B; Maricic, M; Miller, P; Pacifici, R; Recker, R; Sarran, HS; Short, B; Short, MJ | 1 |
| McClung, BL | 1 |
| O'Mahony, D | 1 |
| Ullom-Minnich, P | 1 |
| Rubin, CD | 1 |
| McClung, MR | 1 |
| Arnaud, CD; Chiu, KM; Roe, EB | 1 |
| Cefalu, CA | 1 |
| Body, JJ; Sternon, J | 1 |
| Delmas, PD | 1 |
| Mincey, BA; Moraghan, TJ; Perez, EA | 1 |
| Cox, DA; Heath, H; Plouffe, L | 1 |
| Halbekath, J | 1 |
| Dijkmans, BA; Lems, WF | 1 |
| Baran, DT | 1 |
| Chapurlat, R; Delmas, PD | 1 |
| Chylova, K; Fedelesova, V | 1 |
| Grossman, LD | 1 |
| Deal, C; Lufkin, EG; Wong, M | 1 |
| Lane, NE | 1 |
| Hoon, TS; Leok, GC; Yosipovitch, G | 1 |
| McCarthy, M | 1 |
| Ettinger, B; Forsyth, B; Pressman, A; Tosteson, AN | 1 |
| Wade, JP | 1 |
| Pfeilschifter, J | 1 |
| McClung, B; McClung, M | 1 |
| Bauer, DC; Chapurlat, RD; Cummings, SR; Ewing, SK | 1 |
| Bruder, JM; Rubin, CD; Wang, CY | 1 |
| Sherman, S | 1 |
| Cummings, SR | 1 |
| Hayashi, Y | 1 |
64 review(s) available for raloxifene hydrochloride and Fractures, Bone
| Article | Year |
|---|---|
Fracture risk and treatment in chronic kidney disease.
Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Renal Insufficiency, Chronic; Risk Factors | 2018 |
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cataract; Endometrial Neoplasms; Female; Fractures, Bone; Humans; Medication Adherence; Patient Participation; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; Thromboembolism; Treatment Outcome | 2013 |
Postmenopausal osteoporosis.
Topics: Accidental Falls; Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium; Denosumab; Dietary Supplements; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Risk Reduction Behavior; Teriparatide; Vitamin D; Zoledronic Acid | 2013 |
Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Fractures, Bone; Hip Joint; Humans; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic | 2014 |
Emerging therapeutic concepts for muscle and bone preservation/building.
Topics: Anabolic Agents; Animals; Bone Density; Bone Remodeling; Bone Resorption; Denosumab; Diphosphonates; Fractures, Bone; Humans; Muscle, Skeletal; Osteoporosis; Raloxifene Hydrochloride | 2015 |
Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Clinical Trials as Topic; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2008 |
[Role of estrogen and selective estrogen receptor modulators in anti-aging].
Topics: Aging; Animals; Bone and Bones; Bone Density; Breast Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis; Perimenopause; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators | 2008 |
Treatment of osteoporosis: all the questions we still cannot answer.
Topics: Age Factors; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Fractures, Bone; Hormone Replacement Therapy; Humans; Organometallic Compounds; Osteoporosis; Raloxifene Hydrochloride; Teriparatide; Thiophenes; Time Factors | 2008 |
[Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators | 2008 |
[Treatment of osteoporosis in octogenarians].
Topics: Aged, 80 and over; Attitude to Health; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Diphosphonates; Fractures, Bone; Frail Elderly; Humans; Osteoporosis; Perception; Raloxifene Hydrochloride | 2008 |
[Bone metabolic marker for osteoporosis].
Topics: Acid Phosphatase; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Diphosphonates; Female; Fractures, Bone; Humans; Isoenzymes; Osteoporosis; Peptides; Raloxifene Hydrochloride; Risk Assessment; Tartrate-Resistant Acid Phosphatase | 2009 |
[Evidence for the selective estrogen receptor modulator raloxifene--its pharmacological characteristics, efficacy and safety profiles].
Topics: Bone and Bones; Bone Density; Clinical Trials as Topic; Evidence-Based Medicine; Fractures, Bone; Fractures, Spontaneous; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2009 |
Pharmacotherapeutic management of osteoprosis and osteopenia.
Topics: Algorithms; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitonin; Diphosphonates; Drug Monitoring; Estrogen Replacement Therapy; Fractures, Bone; Humans; Mass Screening; Nurse Practitioners; Nursing Assessment; Osteoporosis; Patient Selection; Practice Guidelines as Topic; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Teriparatide | 2009 |
[Therapeutic considerations on secondary osteoporosis caused by diabetes mellitus].
Topics: Bone Density Conservation Agents; Diabetes Complications; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D; Vitamin K | 2009 |
Approaches to osteoporosis: screening and implementing treatment in clinical practice.
Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Mass Screening; Medication Adherence; Osteoporosis; Practice Guidelines as Topic; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment | 2009 |
Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.
Topics: Breast Neoplasms; Endometrial Neoplasms; Estrogen Receptor Modulators; Female; Fractures, Bone; Humans; Norpregnenes; Raloxifene Hydrochloride; Stroke; Tamoxifen; Thromboembolism | 2009 |
Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis.
Topics: Aged; Bone Density Conservation Agents; Cervical Vertebrae; Diphosphonates; Female; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Thiophenes; Treatment Outcome | 2010 |
[Pharmacotherapy of osteoporosis accompanied by lifestyle-related diseases].
Topics: Adrenergic beta-Antagonists; Animals; Cardiovascular Diseases; Diabetes Complications; Diphosphonates; Dyslipidemias; Fractures, Bone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Life Style; Osteogenesis; Osteoporosis; Raloxifene Hydrochloride; Thiazolidinediones; Vitamin D | 2011 |
Fracture prevention in postmenopausal women.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Calcium, Dietary; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Incidence; Postmenopause; Raloxifene Hydrochloride | 2011 |
The evolution of selective estrogen receptor modulators in osteoporosis therapy.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Fractures, Bone; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Tetrahydronaphthalenes | 2012 |
[Osteoporosis: prevention of bone loss and fractures].
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Diseases, Metabolic; Diagnosis, Differential; Exercise; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Time Factors; Tomography, X-Ray Computed | 2002 |
Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis.
Topics: Aged; Bone Density; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2003 |
[Rehabilitation in osteoporosis].
Topics: Alendronate; Ergonomics; Exercise Therapy; Female; Fractures, Bone; Humans; Male; Osteoporosis; Pain; Physical Therapy Modalities; Psychotherapy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spine | 2003 |
Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.
Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogen Antagonists; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors | 2003 |
[Quality of life before and after medical treatments in osteoporosis patients].
Topics: Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Fractures, Bone; Humans; Osteoporosis; Quality of Life; Raloxifene Hydrochloride; Sickness Impact Profile; Surveys and Questionnaires; Vitamin D | 2004 |
[Postmenopausal osteoporosis].
Topics: Absorptiometry, Photon; Anabolic Agents; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Isoflavones; Motor Activity; Norpregnenes; Osteoporosis, Postmenopausal; Phytoestrogens; Plant Preparations; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Vitamin D; Weight-Bearing | 2004 |
A reappraisal of therapeutic approaches to osteoporosis.
Topics: Alkaline Phosphatase; Bone Density; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride | 2004 |
Pharmacologic prevention of osteoporotic fractures.
Topics: Aged; Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators | 2004 |
[Who are the candidates for the treatment by raloxifen ?].
Topics: Age Factors; Alendronate; Bone and Bones; Bone Density; Diet Therapy; Drug Therapy, Combination; Exercise Therapy; Female; Fractures, Bone; Humans; Motor Activity; Osteoporosis, Postmenopausal; Parathyroid Hormone; Patient Selection; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2004 |
[Evaluation of osteoporosis treatment efficacy by bone mass measurement].
Topics: Absorptiometry, Photon; Bone Density; Diphosphonates; Drug Monitoring; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk; Treatment Outcome | 2004 |
[Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy].
Topics: Animals; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Controlled Clinical Trials as Topic; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Stroke; Transcription Factors | 2005 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide | 2005 |
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide | 2005 |
Raloxifene for prevention of osteoporotic fractures.
Topics: Evidence-Based Medicine; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Patient Selection; Practice Guidelines as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome | 2005 |
Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
Topics: Bone Density; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators | 2005 |
Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Topics: Aged; Bone Density; Clinical Trials as Topic; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Primary Prevention; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2005 |
[Application of anti-resorptive drugs for the treatment of osteoporosis].
Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid | 2006 |
Raloxifene reduces fractures in postmenopausal women with osteoporosis.
Topics: Animals; Bone Density; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome | 2006 |
[Effect of raloxifene as a SERM on bone metabolism].
Topics: Bone and Bones; Bone Density; Bone Resorption; Female; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2006 |
[SERMs for treatment of osteoporosis: state-of-the-art and perspectives].
Topics: Breast Neoplasms; Female; Fractures, Bone; France; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
[Postmenopausal osteoporosis].
Topics: Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Prognosis; Raloxifene Hydrochloride | 2006 |
[Anabolic treatment for osteoporosis: PTH treatment].
Topics: Anabolic Agents; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Fractures, Bone; Humans; Organometallic Compounds; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Thiophenes | 2006 |
[Drug treatment of postmenopausal osteoporosis. What's New in 2006].
Topics: Absorptiometry, Photon; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Body Mass Index; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Femoral Fractures; Follow-Up Studies; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Tablets; Teriparatide; Thiophenes; Time Factors | 2006 |
[Osteoporosis in cancer survivors].
Topics: Age Factors; Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fractures, Bone; Humans; Hypogonadism; Male; Middle Aged; Neoplasms; Osteoporosis; Prostatic Neoplasms; Radiotherapy; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors | 2007 |
Management of postmenopausal osteoporosis for primary care.
Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Family Practice; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Piperidines; Primary Health Care; Raloxifene Hydrochloride; Referral and Consultation; Risk Factors; Sodium Fluoride | 1998 |
Using osteoporosis management to reduce fractures in elderly women.
Topics: Accidental Falls; Aged; Calcitonin; Calcium; Estrogen Antagonists; Estrogen Replacement Therapy; Exercise; Female; Fractures, Bone; Geriatric Assessment; Humans; Nutritional Physiological Phenomena; Osteoporosis, Postmenopausal; Patient Education as Topic; Piperidines; Raloxifene Hydrochloride; Risk Factors | 1999 |
Prevention of osteoporosis and fractures.
Topics: Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Estrogens; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk; Risk Factors; Vitamin D | 1999 |
Treatment considerations in the management of age-related osteoporosis.
Topics: Age Factors; Aged; Bone Density; Calcitonin; Calcium; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk; Risk Factors; Severity of Illness Index | 1999 |
Selective estrogen receptor modulators and postmenopausal health.
Topics: Breast Neoplasms; Chemoprevention; Dementia; Female; Fractures, Bone; Heart Diseases; Humans; Lipoproteins; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Women's Health | 2000 |
Prevention and treatment of osteoporosis in women with breast cancer.
Topics: Aged; Alendronate; Bone Density; Breast Neoplasms; Calcitonin; Diphosphonates; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Ovary; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
[Drug treatment for the treatment of primary osteoporosis].
Topics: Alendronate; Fluorides; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D | 2000 |
Prevention of osteoporotic fractures in post-menopausal women.
Topics: Calcitonin; Calcium; Diphosphonates; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D | 2000 |
[Effect of anti-osteoporosis agents on the incidence of vertebral fractures].
Topics: Alendronate; Bone Density; Calcitonin; Calcium Channel Blockers; Densitometry; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Osteoporosis, Postmenopausal; Postmenopause; Radiography; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Injuries; Spine | 2000 |
Osteoporosis: which current treatments reduce fracture risk?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Calcium Channel Blockers; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators | 2000 |
[Therapeutic strategies for osteoporosis].
Topics: Accidental Falls; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Hormone Replacement Therapy; Humans; Middle Aged; Nutritional Physiological Phenomena; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Vitamin D | 2000 |
The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis.
Topics: Aged; Animals; Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2001 |
An update on glucocorticoid-induced osteoporosis.
Topics: Animals; Bone Density; Bone Remodeling; Diphosphonates; Drug Therapy, Combination; Estrogens; Fractures, Bone; Glucocorticoids; Humans; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Sodium Fluoride; United Kingdom | 2001 |
Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients.
Topics: Adult; Age Factors; Aged; Calcitonin; Calcium; Controlled Clinical Trials as Topic; Densitometry; Diphosphonates; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Exercise; Female; Fractures, Bone; Glucocorticoids; Humans; Male; Meta-Analysis as Topic; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Skin Diseases; Time Factors; Vitamin D | 2001 |
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference.
Topics: Bone Density; Calcium; Consensus Development Conferences, NIH as Topic; Female; Fractures, Bone; Humans; Male; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; United States; Vitamin D | 2001 |
[Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis].
Topics: Administration, Oral; Age Factors; Aged; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Progestins; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Time Factors; Uterine Neoplasms | 2001 |
Pharmacologic therapy for the treatment and prevention of osteoporosis.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Patient Compliance; Patient Selection; Primary Prevention; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome | 2001 |
Evaluation and treatment of postmenopausal osteoporosis.
Topics: Aged; Algorithms; Bone Density; Calcitonin; Calcium; Diphosphonates; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; United States; Women's Health | 2001 |
Preventing and treating osteoporosis: strategies at the millennium.
Topics: Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
[Advancement of treatment for osteoporosis].
Topics: Alendronate; Bone Density; Cholecalciferol; Clinical Trials as Topic; Estrogen Replacement Therapy; Etidronic Acid; Fractures, Bone; Humans; Hydroxycholecalciferols; Osteoporosis; Raloxifene Hydrochloride; Vitamin K 2 | 2002 |
14 trial(s) available for raloxifene hydrochloride and Fractures, Bone
| Article | Year |
|---|---|
Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Cholesterol; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures | 2023 |
Use of health-related quality of life measures to predict health utility in postmenopausal osteoporotic women: results from the Multiple Outcomes of Raloxifene Evaluation study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Australia; Bone Density Conservation Agents; Cervical Vertebrae; European Union; Female; Forecasting; Fractures, Bone; Health Status; Humans; Middle Aged; New Zealand; North America; Osteoporosis, Postmenopausal; Patient Satisfaction; Quality of Life; Raloxifene Hydrochloride; Surveys and Questionnaires | 2013 |
Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Incidence; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Osteoporosis, Postmenopausal; Proportional Hazards Models; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Spine | 2008 |
Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis.
Topics: Aged; Creatinine; Double-Blind Method; Female; Fractures, Bone; Glomerular Filtration Rate; Humans; Kidney; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Renal Insufficiency, Chronic; Selective Estrogen Receptor Modulators | 2011 |
Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
Topics: Adult; Aged; Analysis of Variance; Anthropometry; Bone Density; Bone Diseases, Metabolic; Double-Blind Method; Drug Therapy, Combination; Female; Fluorides; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Phosphates; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2003 |
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.
Topics: Aged; Bone Density; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Recurrence; Risk Factors; Spinal Fractures | 2003 |
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Double-Blind Method; Female; Femoral Neck Fractures; Femur Neck; Fracture Healing; Fractures, Bone; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Placebos; Poisson Distribution; Postmenopause; Proportional Hazards Models; Raloxifene Hydrochloride; Risk; Time Factors; Treatment Outcome | 2005 |
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Topics: Adult; Aged; Breast Neoplasms; Cataract; Cause of Death; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Myocardial Ischemia; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thrombosis; Uterine Neoplasms | 2006 |
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Double-Blind Method; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Safety | 2007 |
Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Cross-Sectional Studies; Depression; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prevalence; Quality of Life; Raloxifene Hydrochloride; Spinal Injuries; Treatment Outcome; Vitamin D | 2007 |
Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial.
Topics: Aged; Coronary Disease; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk; Spinal Fractures | 2008 |
Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Calcium; Female; Fractures, Bone; Humans; Lipid Metabolism; Osteoporosis; Phosphorus; Raloxifene Hydrochloride; Spine | 2008 |
[Treatment of postmenopausal osteoporosis with raloxifene].
Topics: Estrogen Antagonists; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2000 |
Influence of smoking on the antiosteoporotic efficacy of raloxifene.
Topics: Biomarkers; Bone and Bones; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hormones; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Smoking | 2001 |
63 other study(ies) available for raloxifene hydrochloride and Fractures, Bone
| Article | Year |
|---|---|
Ex vivo exposure to calcitonin or raloxifene improves mechanical properties of diseased bone through non-cell mediated mechanisms.
Topics: Animals; Bone Density Conservation Agents; Calcitonin; Fractures, Bone; Male; Mice; Mice, Inbred C57BL; Raloxifene Hydrochloride; Water | 2023 |
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians.
Topics: Bone Diseases, Metabolic; Calcium, Dietary; Denosumab; Diphosphonates; Estrogen Replacement Therapy; Exercise; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Teriparatide; Vitamin D | 2017 |
The estrogen receptor 1 gene affects bone mineral density and osteoporosis treatment efficiency in Slovak postmenopausal women.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Estradiol; Estrogen Receptor alpha; Estrogen Replacement Therapy; Female; Femur Neck; Fractures, Bone; Gene Expression; Genotype; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis; Polymorphism, Single Nucleotide; Postmenopause; Progesterone; Raloxifene Hydrochloride; Slovakia; Treatment Outcome | 2018 |
Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone.
Topics: Animals; Biomechanical Phenomena; Bone Diseases; Calcification, Physiologic; Cancellous Bone; Diaphyses; Drug Therapy, Combination; Femur; Fractures, Bone; Male; Mice, Inbred C57BL; Raloxifene Hydrochloride; Zoledronic Acid | 2019 |
The SERM raloxifene improves diaphyseal fracture healing in mice.
Topics: Animals; Diaphyses; Estrogens; Female; Femoral Fractures; Femur; Fracture Healing; Fractures, Bone; Humans; Mice; Mice, Inbred C57BL; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2013 |
Sensitivity in statistical evaluation of biomarkers.
Topics: Biomarkers; Biomedical Research; Computer Simulation; Data Interpretation, Statistical; Female; Fractures, Bone; Humans; Lumbar Vertebrae; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome | 2013 |
Comparison of two ethnic populations using distribution adjusted mean.
Topics: Algorithms; Analysis of Variance; Bone Density; Computer Simulation; Cross-Cultural Comparison; Data Interpretation, Statistical; Ethnicity; Fractures, Bone; Humans; Japan; Monte Carlo Method; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Sample Size; Selective Estrogen Receptor Modulators; Treatment Outcome | 2013 |
Evaluation of the prescription of osteoporosis treatment after a major osteoporotic fracture.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcium; Dietary Supplements; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; France; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Prescriptions; Raloxifene Hydrochloride; Retrospective Studies; Thiophenes; Treatment Outcome; Vitamin D; Wrist Injuries; Zoledronic Acid | 2014 |
Use of anti-osteoporotic drugs in central Norway after a forearm fracture.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug Prescriptions; Female; Forearm; Forearm Injuries; Fractures, Bone; Glucocorticoids; Humans; Male; Middle Aged; Norway; Osteoporosis; Patient Compliance; Raloxifene Hydrochloride; Secondary Prevention; Teriparatide | 2015 |
Proportion and Characteristics of Patients in Sweden Remaining at High Risk of Fracture Despite Prior Treatment.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Estrogen Antagonists; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risk; Sweden | 2016 |
Review of comparative effectiveness of treatments to prevent fractures.
Topics: Bone Density Conservation Agents; Cardiovascular Diseases; Clinical Trials as Topic; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride | 2008 |
Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Drug Prescriptions; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Patient Compliance; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Sex Distribution; Spinal Fractures; Treatment Outcome | 2009 |
Vitamin D status and response to treatment in post-menopausal osteoporosis.
Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Confounding Factors, Epidemiologic; Dietary Supplements; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Logistic Models; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2009 |
[Treatment of osteoporosis in the elderly: what is the evidence?].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Teriparatide; Treatment Outcome | 2008 |
[4/5. Osteoporosis].
Topics: Administration, Oral; Adult; Bone Density Conservation Agents; Calcium; Fractures, Bone; Humans; Menopause; Middle Aged; Osteoporosis; Raloxifene Hydrochloride | 2009 |
Biomechanical and histological outcome of combined raloxifene-estrogen therapy on skeletal and reproductive tissues.
Topics: Animals; Body Weight; Bone and Bones; Bone Density; Drug Therapy, Combination; Estrogens; Female; Femur; Fractures, Bone; Organ Specificity; Osteopetrosis; Raloxifene Hydrochloride; Rats; Rats, Wistar; Risk; Tibia; Uterus | 2010 |
Another selective estrogen-receptor modulator for osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism | 2010 |
Adjustment for the measurement error in evaluating biomarkers.
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Computer Simulation; Data Interpretation, Statistical; Evaluation Studies as Topic; Female; Fractures, Bone; Humans; Models, Statistical; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Reproducibility of Results | 2010 |
Fracture risk in early postmenopausal women assessed using FRAX.
Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; France; Hip Fractures; Humans; Middle Aged; Models, Statistical; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors | 2010 |
Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer.
Topics: Aged; Algorithms; Breast Neoplasms; Cost-Benefit Analysis; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride | 2010 |
Tipping the balance for the primary prevention of breast cancer.
Topics: Adult; Age Factors; Aged; Anticarcinogenic Agents; Biomarkers, Tumor; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Confounding Factors, Epidemiologic; Estradiol; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Risk Assessment; Sample Size; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Treatment Outcome | 2010 |
Third-generation SERMs may face uphill battle.
Topics: Anticarcinogenic Agents; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Drug Industry; Estradiol; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Patents as Topic; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; United States; United States Food and Drug Administration | 2010 |
[Current therapeutic means].
Topics: Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Reproducibility of Results | 2002 |
[CBO guideline 'Osteoporosis' (second revision].
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Bone Density; Calcium, Dietary; Dietary Supplements; Female; Fractures, Bone; Humans; Male; Menopause; Middle Aged; Netherlands; Osteoporosis; Practice Guidelines as Topic; Prevalence; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Sex Factors; Societies, Medical; Vitamin D | 2002 |
[Patients with fractures are in the front line for osteoporosis treatment but how to treat?].
Topics: Alendronate; Bone Density; Calcitonin; Etidronic Acid; Fractures, Bone; Health Services Accessibility; Humans; Osteoporosis; Physician's Role; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors | 2001 |
Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats.
Topics: Alendronate; Animals; Estrogens; Female; Fracture Healing; Fractures, Bone; Ovariectomy; Radiography; Raloxifene Hydrochloride; Rats | 2002 |
[Osteoporosis: diagnosis, prevention and treatment].
Topics: Adult; Aged; Calcitonin; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Injections, Intramuscular; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators | 2002 |
[Diabetes, Conn syndrome and osteoporosis. What is new in diagnosis and therapy?].
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diphosphonates; Estrogen Antagonists; Female; Fractures, Bone; Humans; Hyperaldosteronism; Hyperglycemia; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators | 2003 |
[Osteoporosis therapy compared. More solid bones with bisphosphonates].
Topics: Alendronate; Bone Density; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors | 2003 |
The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.
Topics: Acid Phosphatase; Age Factors; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Calcium; Collagen Type I; Data Interpretation, Statistical; Female; Fractures, Bone; Humans; Long-Term Care; Nursing Homes; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphates; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Sex Factors; Time Factors; Vitamin D | 2004 |
Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care.
Topics: Aged; Bone Density; Diphosphonates; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Women's Health | 2004 |
Compliance with drug therapies for the treatment and prevention of osteoporosis.
Topics: Age Factors; Aged; Aged, 80 and over; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Fractures, Bone; Health Care Costs; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Osteoporosis; Patient Compliance; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors | 2004 |
[Bone quality and raloxifene].
Topics: Bone and Bones; Calcification, Physiologic; Fractures, Bone; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2004 |
Quantifying the indirect treatment effect via surrogate markers.
Topics: Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Collagen; Collagen Type I; Data Interpretation, Statistical; Fractures, Bone; Osteocalcin; Osteoporosis; Peptides; Proportional Hazards Models; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic | 2006 |
Cost-effectiveness strategies to treat osteoporosis in elderly women.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcitonin; Cost Savings; Cost-Benefit Analysis; Diphosphonates; Female; Fractures, Bone; Humans; Osteoporosis; Parathyroid Hormone; Quality of Life; Raloxifene Hydrochloride; Treatment Outcome | 2006 |
[New therapeutic approaches to osteoporosis].
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride | 2006 |
Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis.
Topics: Aged; Asian People; Bone Density Conservation Agents; China; Female; Fractures, Bone; Humans; Incidence; Japan; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride | 2006 |
Effectiveness of raloxifene on bone mineral density and serum lipid levels in post-menopausal women with low BMD after discontinuation of hormone replacement therapy.
Topics: Absorptiometry, Photon; Aged; Body Mass Index; Bone Density; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Retrospective Studies; Time Factors | 2006 |
Quantifying the treatment effect explained by markers in the presence of measurement error.
Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Data Interpretation, Statistical; Fractures, Bone; Humans; Logistic Models; Osteoporosis; Raloxifene Hydrochloride; Treatment Outcome | 2007 |
Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Italy; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk Factors; Vitamin D | 2006 |
[Osteoporosis priority: Reduce the number of fractures].
Topics: Absorptiometry, Photon; Age Factors; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Fractures, Bone; Humans; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Teriparatide; Thiophenes; Time Factors | 2006 |
Bone quality: an empty term.
Topics: Bone and Bones; Bone Density; Bone Resorption; Diphosphonates; Fractures, Bone; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2007 |
Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Cost-Benefit Analysis; Female; Fractures, Bone; Humans; Middle Aged; Models, Econometric; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Risk; Thromboembolism | 2007 |
Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone.
Topics: Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Dogs; Female; Femur Neck; Fractures, Bone; Raloxifene Hydrochloride; Trabecular Meshwork | 2007 |
Osteoporosis: non-hormonal treatment.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Vitamin D; Women's Health | 2007 |
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.
Topics: Adult; Age Factors; Aged; Alendronate; Body Mass Index; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Italy; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Treatment Failure | 2008 |
Summaries for patients. Drug therapy for osteoporosis.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors | 2008 |
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors | 2008 |
Effects of raloxifene in postmenopausal women.
Topics: Bone Density; Estrogen Antagonists; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Research Design | 1998 |
Tamoxifen for prevention of breast cancer.
Topics: Adult; Breast Neoplasms; Cerebrovascular Disorders; Drug Costs; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Fractures, Bone; Humans; Middle Aged; Myocardial Infarction; Osteoporosis, Postmenopausal; Piperidines; Placebos; Pulmonary Embolism; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Thrombophlebitis | 1999 |
Prevention of corticosteroid-induced osteoporosis and fractures.
Topics: Adrenal Cortex Hormones; Bone Density; Calcitonin; Calcitriol; Calcium Channel Agonists; Estrogen Antagonists; Fractures, Bone; Hormone Replacement Therapy; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride | 1999 |
Therapy for fracture prevention.
Topics: Bone Density; Clinical Trials as Topic; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk | 1999 |
Raloxifene therapy in the reduction of fractures.
Topics: Aged; Blood Coagulation Factors; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Estrogen Receptor Modulators; Female; Fractures, Bone; Humans; Incidence; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome | 2000 |
[Raloxifene (Celvista, Evista)].
Topics: Arteriosclerosis; Bone and Bones; Breast Neoplasms; Controlled Clinical Trials as Topic; Endometrium; Female; Fractures, Bone; Heart Diseases; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Thromboembolism; Uterine Hemorrhage | 2000 |
How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
Topics: Aged; Alendronate; Bone and Bones; Bone Demineralization, Pathologic; Estrogen Antagonists; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk | 2000 |
Raloxifene therapy.
Topics: Accidental Falls; Central Nervous System; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2000 |
Alendronic acid in primary prevention: new indication. No reduction in fracture risk.
Topics: Alendronate; Clinical Trials as Topic; Cost-Benefit Analysis; Esophagitis; Estrogen Replacement Therapy; Female; Fractures, Bone; France; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome | 2000 |
Drug information needs clarification.
Topics: Aged; Cardiovascular Diseases; Clinical Trials as Topic; Estrogen Antagonists; Female; Fractures, Bone; Humans; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Reproducibility of Results; Risk Factors | 2001 |
Raloxifene fails to slow cognitive decline in older women.
Topics: Aged; Cognition Disorders; Female; Fractures, Bone; Humans; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2001 |
Initiation of osteoporosis treatment after bone mineral density testing.
Topics: Absorptiometry, Photon; Age Factors; Aged; Bone Density; Cohort Studies; Decision Making; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Fractures, Bone; Glucocorticoids; Health Care Rationing; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators | 2001 |
Rheumatology: 15. Osteoporosis.
Topics: Bone Density; Calcitonin; Calcium, Dietary; Dietary Supplements; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Life Style; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Thoracic Vertebrae; Vitamin D | 2001 |
Raloxifene: new preparation. Not better than oestrogen.
Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Uterine Neoplasms | 1999 |
The paradox of small changes in bone density and reductions in risk of fracture with raloxifene.
Topics: Bone Density; Fractures, Bone; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2001 |